Literature DB >> 24958967

Gemcitabine and Vinorelbine (GemVin) Regimen.

Elizabeth Y Shang1, Dominic A Solimando1, J Aubrey Waddell1.   

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Entities:  

Year:  2014        PMID： 24958967      PMCID： PMC4062729          DOI： 10.1310/hpj4906-508

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  55 in total

1.  Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT.

Authors:  Elif Suyanı; Gülsan Türköz Sucak; Şahika Zeynep Akı; Zeynep Arzu Yeğin; Zübeyde Nur Özkurt; Münci Yağcı
Journal:  Ann Hematol       Date:  2010-11-12       Impact factor: 3.673

2.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authors:  Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2006-05-08       Impact factor: 44.544

3.  A randomized phase II study of vinorelbine plus gemcitabine with/without cisplatin against inoperable non-small-cell lung cancer previously untreated.

Authors:  Yuh-Min Chen; Reury-Perng Perng; Jen-Fu Shih; Chun-Ming Tsai; Jacqueline Whang-Peng
Journal:  Lung Cancer       Date:  2005-03       Impact factor: 5.705

4.  Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer.

Authors:  R C Lilenbaum; C-S Chen; T Chidiac; P O Schwarzenberger; M Thant; M Versola; S R Lane
Journal:  Ann Oncol       Date:  2005-01       Impact factor: 32.976

5.  A randomized phase II non-comparative study of pemetrexed‑carboplatin and gemcitabine‑vinorelbine in anthracycline- and taxane-pretreated advanced breast cancer patients.

Authors:  Dino Amadori; Eva Carrasco; Siegfried Roesel; Roberto Labianca; Beatrice Uziely; Victoria Soldatenkova; Valerie Moreau; Durisala Desaiah; Thomas Bauknecht; Miguel Martin
Journal:  Int J Oncol       Date:  2013-03-28       Impact factor: 5.650

6.  A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (Stage IIIB/IV) non-small cell lung cancer.

Authors:  Y M Chen; R P Perng; K Y Yang; T W Liu; C M Tsai; J Ming-Liu; J Whang-Peng
Journal:  Chest       Date:  2000-06       Impact factor: 9.410

7.  Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer.

Authors:  E H Tan; A Szczesna; M Krzakowski; H N Macha; U Gatzemeier; K Mattson; M Wernli; P Reiterer; R Hui; J Von Pawel; O Bertetto; J C Pouget; J P Burillon; Y Parlier; R Abratt
Journal:  Lung Cancer       Date:  2005-08       Impact factor: 5.705

8.  Gemcitabine/vinorelbine in metastatic breast cancer patients previously treated with anthracyclines: results of a phase II trial.

Authors:  F Lobo; J A Virizuela; F J Dorta; J Florián; M Lomas; E Jiménez; P López; V Casado; A Léon; L G Estévez; M Dómine
Journal:  Clin Breast Cancer       Date:  2003-04       Impact factor: 3.225

9.  Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim.

Authors:  A Spencer; K Reed; C Arthur
Journal:  Intern Med J       Date:  2007-06-02       Impact factor: 2.048

10.  Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST).

Authors:  C Boni; M Tiseo; L Boni; E Baldini; F Recchia; C Barone; F Grossi; D Germano; E Matano; G Marini; R Labianca; F Di Costanzo; A Bagnulo; C Pennucci; C Caroti; M Mencoboni; F Zanelli; T Prochilo; M A Cafferata; A Ardizzoni
Journal:  Br J Cancer       Date:  2012-01-12       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.